Neutrophil-to-lymphocyte ratio is a reliable marker of treatment response in rheumatoid arthritis patients during tocilizumab therapy

References

• Assayag D, Lee JS, King TE. Jr. Rheumatoid arthritis associated interstitial lung disease: a review. Medicina (B Aires). 2014;74: 158–65.
   PubMed Web of Science ®Google Scholar
• Willemze A, Toes RE, Huizinga TW, Trouw LA. New biomarkers in rheumatoid arthritis. Neth J Med. 2012;70:392–9.
   PubMed Web of Science ®Google Scholar
• Sanmarti R, Ruiz-Esquide V, Hernandez MV. Rheumatoid arthritis: a clinical overview of new diagnostic and treatment approaches. Curr Top Med Chem. 2013;13:698–704.
   PubMed Web of Science ®Google Scholar
• Karimifar M, Salesi M, Farajzadegan Z. The association of anti-CCP1 antibodies with disease activity score 28 (DAS-28) in rheumatoid arthritis. Adv Biomed Res. 2012;1:30.
   PubMedGoogle Scholar
• Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964–75.
   PubMed Web of Science ®Google Scholar
• Shetty A, Hanson R, Korsten P, Shawagfeh M, Arami S, Volkov S, et al. Tocilizumab in the treatment of rheumatoid arthritis and beyond. Drug Des Devel Ther. 2014;8:349–64.
   PubMed Web of Science ®Google Scholar
• Bari SF, Khan A, Lawson T. C reactive protein may not be reliable as a marker of severe bacterial infection in patients receiving tocilizumab. BMJ Case Rep. 2013. doi: 10.1136/bcr-2013-010423.
   PubMedGoogle Scholar
• Fujiwara H, Nishimoto N, Hamano Y, Asanuma N, Miki S, Kasayama S, et al. Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases. Mod Rheumatol. 2009;19:64–8.
   PubMed Web of Science ®Google Scholar
• Nguyen MT, Podenphant J, Ravn P. Three cases of severely disseminated Staphylococcus aureus infection in patients treated with tocilizumab. BMJ Case Rep. 2013. doi: 10.1136/bcr-2012-007413.
   Google Scholar
• Hirao M, Nampei A, Shi K, Yoshikawa H, Nishimoto N, Hashimoto J. Diagnostic features of mild cellulitis phlegmon in patients with rheumatoid arthritis treated with tocilizumab: a report of two cases. Mod Rheumatol. 2011;21:673–7.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum. 2005;52:2625–36.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;42:244–57.
   PubMed Web of Science ®Google Scholar
• Balta S, Demirkol S, Unlu M, Arslan Z, Celik T. Neutrophil to lymphocyte ratio may be predict of mortality in all conditions. Br J Cancer. 2013;109:3125–6.
   PubMed Web of Science ®Google Scholar
• Fu H, Qin B, Hu Z, Ma N, Yang M, Wei T, et al. Neutrophil- and platelet-to-lymphocyte ratios are correlated with disease activity in rheumatoid arthritis. Clin Lab. 2015;61:269–73.
   PubMed Web of Science ®Google Scholar
• Uslu AU, Kucuk A, Sahin A, Ugan Y, Yilmaz R, Gungor T, et al. Two new inflammatory markers associated with disease activity score-28 in patients with rheumatoid arthritis: neutrophil-lymphocyte ratio and platelet-lymphocyte ratio. Int J Rheum Dis. 2015;18:731–5.
   PubMed Web of Science ®Google Scholar
• Talstad I, Haugen HF. The relationship between the erythrocyte sedimentation rate (ESR) and plasma proteins in clinical materials and models. Scand J Clin Lab Invest. 1979;39:519–24.
   PubMed Web of Science ®Google Scholar
• Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990;265:621–36.
   PubMed Web of Science ®Google Scholar
• Castell JV, Gomez-Lechon MJ, David M, Andus T, Geiger T, Trullenque R, et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett. 1989;242:237–9.
   PubMed Web of Science ®Google Scholar
• Snir A, Kessel A, Haj T, Rosner I, Slobodin G, Toubi E. Anti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapy. Clin Exp Rheumatol. 2011;29:697–700.
   PubMed Web of Science ®Google Scholar
• Uson J, Balsa A, Pascual-Salcedo D, Cabezas JA, Gonzalez-Tarrio JM, Martin-Mola E, et al. Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies. J Rheumatol. 1997;24:2069–75.
   PubMed Web of Science ®Google Scholar
• Desgeorges A, Gabay C, Silacci P, Novick D, Roux-Lombard P, Grau G, et al. Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. J Rheumatol. 1997;24:1510–16.
   PubMed Web of Science ®Google Scholar
• Boyraz I, Koc B, Boyaci A, Tutoglu A, Sarman H, Ozkan H. Ratio of neutrophil/lymphocyte and platelet/lymphocyte in patient with ankylosing spondylitis that are treating with anti-TNF. Int J Clin Exp Med. 2014;7:2912–15.
   PubMed Web of Science ®Google Scholar
• Cascao R, Rosario HS, Souto-Carneiro MM, Fonseca JE. Neutrophils in rheumatoid arthritis: More than simple final effectors. Autoimmun Rev. 2010;9:531–5.
   PubMed Web of Science ®Google Scholar
• Eyles JL, Roberts AW, Metcalf D, Wicks IP. Granulocyte colony-stimulating factor and neutrophils-forgotten mediators of inflammatory disease. Nat Clin Pract Rheumatol. 2006;2:500–10.
   PubMedGoogle Scholar
• Kaplan MJ. Role of neutrophils in systemic autoimmune diseases. Arthritis Res Ther. 2013;15:219.
   PubMed Web of Science ®Google Scholar
• Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol. 1991;21:2575–9.
   PubMed Web of Science ®Google Scholar
• Alex P, Szodoray P, Knowlton N, Dozmorov IM, Turner M, Frank MB, et al. Multiplex serum cytokine monitoring as a prognostic tool in rheumatoid arthritis. Clin Exp Rheumatol. 2007;25:584–92.
   PubMed Web of Science ®Google Scholar
• Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 1999;42:963–70.
   PubMed Web of Science ®Google Scholar
• Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 1999;103:1345–52.
   PubMed Web of Science ®Google Scholar
• Pelletier M, Maggi L, Micheletti A, Lazzeri E, Tamassia N, Costantini C, et al. Evidence for a cross-talk between human neutrophils and Th17 cells. Blood. 2010;115:335–43.
   PubMed Web of Science ®Google Scholar
• den Broeder AA, Wanten GJ, Oyen WJ, Naber T, van Riel PL, Barrera P. Neutrophil migration and production of reactive oxygen species during treatment with a fully human anti-tumor necrosis factor-alpha monoclonal antibody in patients with rheumatoid arthritis. J Rheumatol. 2003;30:232–7.
   PubMed Web of Science ®Google Scholar
• Clarke D, Johnson PW, Banks RE, Storr M, Kinsey SE, Johnson R, et al. Effects of interleukin 6 administration on platelets and haemopoietic progenitor cells in peripheral blood. Cytokine. 1996;8:717–23.
   PubMed Web of Science ®Google Scholar
• Stahl CP, Zucker-Franklin D, Evatt BL, Winton EF. Effects of human interleukin-6 on megakaryocyte development and thrombocytopoiesis in primates. Blood. 1991;78:1467–75.
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Kimura H, Shikama Y, Uchida T, Kariyone S, Hirano T, et al. Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood. 1989;74:1241–4.
   PubMed Web of Science ®Google Scholar
• Funahashi K, Koyano S, Miura T, Hagiwara T, Okuda K, Matsubara T. Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level. Mod Rheumatol. 2009;19:507–12.
   PubMed Web of Science ®Google Scholar
• Bykerk VP, Lie E, Bartlett SJ, Alten R, Boonen A, Christensen R, et al. Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare Workshop. J Rheumatol. 2014;41:799–809.
   PubMed Web of Science ®Google Scholar
• Yazici Y, Erkan D, Kulman I, Belostocki K, Harrison MJ. Decreased flares of rheumatoid arthritis during the first year of etanercept treatment: further evidence of clinical effectiveness in the “real world”. Ann Rheum Dis. 2002;61:638–40.
   PubMed Web of Science ®Google Scholar
• Bartlett SJ, Bykerk VP, Cooksey R, Choy EH, Alten R, Christensen R, et al. Feasibility and domain validation of rheumatoid arthritis (RA) flare core domain set: report of the OMERACT 2014 RA flare group plenary. J Rheumatol. 2015;42:2185–9.
   PubMed Web of Science ®Google Scholar